Taveras Arthur 4
4 · X4 Pharmaceuticals, Inc · Filed Nov 2, 2023
Insider Transaction Report
Form 4
Taveras Arthur
Chief Scientific Officer
Transactions
- Award
Common Stock
2023-10-31+230,645→ 317,018 total
Footnotes (1)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.